Table 1

Base case cost-effectiveness results for age and gender subgroups

TKRUKR∆ QALYs∆ Costs (£)ICER (probability UKR cost-effective*)
QALYsCosts (£)QALYsCosts (£)
Male,
<60 years
10.28
(10.07 to 10.47)
15 357
(14 704 to 16 019)
10.39
(10.11 to 10.70)
14 134
(13 489 to 14 810)
0.12
(− 0.19 to 0.47)
−1223
(−1439 to − 1014)
UKR dominant (87%)
Male,
60–75 years
8.61
(8.50 to 8.70)
13 307
(12 584 to 14 037)
8.81
(8.63 to 8.97)
11 952
(11 246 to 12 704)
0.20
(0.01 to 0.39)
−1355
(− 1610 to − 1122)
UKR dominant (100%)
Male,
75+ years
5.61
(5.49 to 5.73)
11 454
(10 506 to 12 511)
5.80
(5.64 to 5.97)
9450
(8442 to 10 631)
0.19
(0.02 to 0.37)
−2005
(−2361 to −1521)
UKR dominant (100%)
Female,
<60 years
10.68
(10.50 to 10.89)
16 961
(16 101 to 17 899)
10.78
(10.42 to 11.09)
16 360
(15 514 to 17 273)
0.10
(− 0.33 to 0.47)
−601
(− 887 to −350)
UKR dominant (72%)
Female,
60–75 years
8.96
(8.84 to 9.06)
13 814
(13 089 to 14 602)
9.24
(9.04 to 9.43)
12 878
(12 068 to 13 702)
0.28
(0.05 to 0.50)
−935
(−1186 to − 710)
UKR dominant (100%)
Female,
75+ years
6.02
(5.82 to 6.15)
11 410
(10 541 to 12 378)
6.46
(6.20 to 6.69)
10 308
(9312 to 11 378)
0.44
(0.18 to 0.71)
−1102
(−1646 to −695)
UKR dominant (100%)
  • Expected (mean) values with 95% CIs in parentheses. UKR is considered ‘dominant’ if it is expected to improve health outcomes and reduce healthcare costs.

  • *Given a cost-effectiveness threshold of £20 000.

  • ICER, incremental cost-effectiveness ratio; QALYs, quality-adjusted life years; TKR, total knee replacement; UKR, unicompartmental knee replacement.